Table 4 Variations existing in the efficacy of nine novel biologics

 − 1.56

(− 7.06, 3.94)

Eculizumab

 − 1.92

(− 7.89, 4.05)

 − 0.36

(− 7.19, 6.47)

Zilucoplan

 − 2.17

(− 7.97, 3.63)

 − 0.61

(− 7.28, 6.06)

 − 0.25

(− 7.32, 6.82)

Belimumab

 − 2.46

(− 7.70, 2.78)

 − 0.90

(− 7.10, 5.30)

 − 0.54

(− 7.16, 6.08)

 − 0.29

(− 6.76, 6.18)

Ravulizumab

 − 2.77

(− 7.67, 2.14)

 − 1.20

(− 7.11, 4.70)

 − 0.84

(− 7.19, 5.51)

 − 0.59

(− 6.78, 5.59)

 − 0.30

(− 5.97, 5.36)

Efgartigimod

 − 2.74

(− 7.46, 1.99)

 − 1.18

(− 6.95, 4.59)

 − 0.82

(− 7.04, 5.40)

 − 0.57

(− 6.62, 5.49)

 − 0.28

(− 5.80, 5.25)

0.03

(− 5.17, 5.22)

Rituximab

 − 3.84

(− 9.34, 1.66)

 − 2.28

(− 8.70, 4.14)

 − 1.92

(− 8.75, 4.91)

 − 1.67

(− 8.35, 5.01)

 − 1.38

(− 7.58, 4.82)

 − 1.08

(− 6.98, 4.83)

 − 1.10

(− 6.87, 4.67)

Rozanolixizumab

 − 4.46

(− 7.57, − 1.35)

 − 2.90

(− 7.44, 1.64)

 − 2.54

(− 7.64, 2.56)

 − 2.29

(− 7.19, 2.61)

 − 2.00

(− 6.22, 2.22)

 − 1.70

(− 5.48, 2.09)

 − 1.72

(− 5.28, 1.84)

 − 0.62

(− 5.16, 3.92)

Placebo